Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592

NCT06366451 is registered in ClinicalTrials.gov with Presage Biosciences as lead sponsor.

NCT NCT06366451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06366451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592
Lead sponsor
Presage Biosciences
Phase
Phase 1
Overall status
Completed
Start date
May 22, 2024
Completion date
March 25, 2026
Enrollment
17 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma